We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Supreme Court has asked the solicitor general to consider if a lower court erred in mandating that Novartis wait six months after approval of a biosimilar before going to market. Read More
The second highest court in the land rejected Mylan’s requested rehearing in two patent lawsuits, leaving the company with few options for avoiding the cases. Read More
The introduction of biosimilars to certain European countries has lowered drug prices by 50 percent to 60 percent in certain therapy areas, a report says. Read More
Senate Judiciary Committee members and generics makers in June both sung the praises of a bill aimed at preventing branded drugmakers from restricting access to their products. Read More
The U.S. Supreme Court has paved the way for the possibility of drugmakers collecting enhanced damages in patent cases, striking down an appellate standard in a unanimous 8-0 decision. Read More
AstraZeneca’s lawsuit against the FDA over the exclusivity of one of its drugs is a “transparent” effort to stifle generic competition for the blockbuster anti-cholesterol drug Crestor, the FDA said in its response to the suit. Read More
Pfizer has pledged to communicate all the risks associated with opioids in future ads under an unusual accord it reached with the city of Chicago. Read More
The UK’s National Institute for Health and Care Excellence declined to recommend Bristol-Myers Squibb’s Opdivo for reimbursement in the treatment of advanced renal cell carcinoma. Read More